L21-iPaD: An efficient method for drug-pathway association pairs inference

Pathway-based drug discovery overcomes the disadvantages of the “one drug-one target” method, which aims to find the effective drugs to act on single targets. The current method “iPaD” identities the drug-pathway association pairs by taking the lasso-type penalty on the drug-pathway association matrix. In order to enhance the robustness of the methods and be more effective to find the novel drug-pathway association pairs, we introduce a new method named “L2,1-iPaD”. Compared with the iPaD method, we impose the L2,1-norm constraint on the drug-pathway association coefficient matrix. By applying our method to a real widely datasets (CCLE dataset), we demonstrate that our method is superior to the iPaD method. And our method can obtain the smaller P-values than the iPaD method by performing permutation test to assess the significance of the identified drug-pathway association pairs. More importantly, compared with the iPaD method, our method can identify larger numbers of validated drug-pathway association pairs. The experimental results on the real dataset demonstrate the effectiveness of our method.

[1]  P. Secchiero,et al.  Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. , 2009, Blood.

[2]  Hongyu Zhao,et al.  Drug target inference through pathway analysis of genomics data. , 2013, Advanced drug delivery reviews.

[3]  Y. Nesterov.  A method for solving the convex programming problem with convergence rate O(1/k^2) , 1983 .

[4]  Feiping Nie,et al.  Robust Manifold Nonnegative Matrix Factorization , 2014, ACM Trans. Knowl. Discov. Data.

[5]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[6]  Hongyu Zhao,et al.  Efficient Drug-Pathway Association Analysis via Integrative Penalized Matrix Decomposition , 2016, IEEE/ACM Transactions on Computational Biology and Bioinformatics.

[7]  Feiping Nie,et al.  Multi-Class L2,1-Norm Support Vector Machine , 2011, 2011 IEEE 11th International Conference on Data Mining.

[8]  Yong Xu,et al.  Extracting plants core genes responding to abiotic stresses by penalized matrix decomposition , 2012, Comput. Biol. Medicine.

[9]  Huan Liu,et al.  Discriminant Analysis for Unsupervised Feature Selection , 2014, SDM.

[10]  Robert Tibshirani,et al.  Spectral Regularization Algorithms for Learning Large Incomplete Matrices , 2010, J. Mach. Learn. Res..

[11]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Feiping Nie,et al.  Multi-View Clustering and Feature Learning via Structured Sparsity , 2013, ICML.

[13]  Hongyu Zhao,et al.  iFad: an integrative factor analysis model for drug-pathway association inference , 2012, Bioinform..

[14]  Shannon L. Risacher,et al.  Sparse multi-task regression and feature selection to identify brain imaging predictors for memory performance , 2011, 2011 International Conference on Computer Vision.

[15]  Jens Pietzsch,et al.  Cyclin-Dependent Kinases (Cdk) as Targets for Cancer Therapy and Imaging , 2011 .

[16]  Howard W Mielke,et al.  The Fisher-Pitman Permutation Test: An Attractive Alternative to the F Test , 2002, Psychological reports.

[17]  Hongyuan Zha,et al.  {\it R}$_{\mbox{1}}$-PCA: rotational invariant {\it L}$_{\mbox{1}}$-norm principal component analysis for robust subspace factorization , 2006, ICML 2006.

[18]  J. Cicenas,et al.  Highlights of the Latest Advances in Research on CDK Inhibitors , 2014, Cancers.

[19]  Feiping Nie,et al.  Non-Greedy L21-Norm Maximization for Principal Component Analysis , 2016, ArXiv.

[20]  Hongyu Zhao,et al.  FacPad: Bayesian sparse factor modeling for the inference of pathways responsive to drug treatment , 2012, Bioinform..